Micromet Key facts:
Business
Design and development of novel antibody-based drugs
Markets
Cancer, Inflammation, Autoimmunity
Drug Pipeline
MT201, a fully human antibody for treatment of tumors, in phase II
MT103, a BiTE™ molecule for treatment of B cell lymphomas and leukemias, in phase I
MT110, a BiTE™ molecule for treatment of carcinomas, preclinical
MT203, a human antibody for treatment of inflammatory diseases, preclinical
D93 (humanized antibody), Solid Tumors, Pre-clinical
Additional BiTE™s and human antibodies in drug discovery
Technologies
BiTE™
BiTE™s are a novel format of bispecific antibody derivatives. They are unique in their ability to activate the body’s killer T cells against target cells. This novel mode of action translates into outstanding potency and specificity in target cell elimination.
SCA (single-chain antibodies)
SCAs are small antibody fragments, which are cost-effective to produce and extremely versatile for protein engineering. They provide an ideal structural basis for the development of novel drug formats as exemplified by their use in BiTE™ drugs.
Partners
Serono, MedImmune, Enzon, Boehringer Ingelheim
Status: Reverse merger with CNVX in Q2,2006
Proposed Ticker: MITI
Foundation
1993 as spin-off from the Institute for Immunology, Munich University
Pipeline
micromet.de
Most Interesting Research Paper:
nature.com
Reverse Merger Details and Future Goals:
biz.yahoo.com
micromet.de
Thanks for Looking! |
